NIH Awards $7.8M for Rare Disease Network to Advance Clinical Research in MG
The National Institutes of Health (NIH) has awarded $7.8 million for the launch of a rare disease network, called…
Articles by Ana Pena, PhD
Soliris Has Durable Efficacy in Japanese, Caucasian gMG Patients Alike, Extension Data Show
Treatment with Soliris (eculizumab) provides comparable and sustained improvements in daily living and muscle strength in Japanese and Caucasian patients with…
Refractory MG Poses Burden to U.S. Healthcare System, Needs Better Treatments, Study Finds
People with myastenia gravis (MG) whose disease is refractory, or resistant, to conventional therapies, are more likely to have…
Differences in Gene Activity May Explain Why Some Patients Have Difficult-to-treat Eye Disease, Study Shows
Examining differences in the activity of certain genes may help explain why some patients with myasthenia gravis (MG) develop…
Dropouts in Placebo Groups Due to Adverse Events Are Low in MG Clinical Trials, Study Shows
Placebo-treated myasthenia gravis (MG) patients experience as many adverse events as those receiving an active treatment during clinical trials,…
Computational Model Identifies Candidate Therapies Based on MG Risk Genes
Researchers have identified five candidate therapies for treating myasthenia gravis (MG)Â by using a…
Prograf May Be Effective Medication for Myasthenia Gravis, Analysis Shows
Prograf (Tacrolimus) may be a beneficial treatment for people with myasthenia gravis (MG), helping reduce steroid use and…
MG-ADL Symptom Scale Would Benefit from Questions on Generalized Weakness, Study Says
MG-ADL, a patient-reported scale commonly used to address symptom severity in myasthenia gravis (MG), has a poor sensitivity…
Common Clinical Scales Insufficient to Evaluate Swallowing Problems in MG Patients, Study Reports
Commonly used clinical scales to measure symptom severity in myasthenia…
Gut Microbiota Differs in Myasthenia Gravis Patients, Pilot Study Reports
Gut microbiota is altered in people with myasthenia gravis (MG), opening the door for exploring the use of microbiota-modulating…